曲美他嗪治疗缺血性心脏病心力衰竭效果观察

Effect observation of Trimetazidine in treatment of ischemic heart failure

目的曲美他嗪治疗缺血性心脏病心力衰竭的治疗效果。方法 90例缺血性心脏病心力衰竭患者随机分为观察组和对照组各45例。对照组给予常规治疗,观察组在对照组治疗基础上应用曲美他嗪,观察2组治疗前后左室射血分数(LVEF)、左室舒张末期内径(LVEDD)变化及临床疗效。结果 2组治疗后LVEDD降低,LVEF升高,与治疗前比较差异均有统计学意义(P<0.05);且观察组改善情况优于对照组,差异均有统计学意义(P<0.05)。观察组总有效率为91.1%高于对照组的71.1%,差异有统计学意义(P<0.05)。结论曲美他嗪治疗缺血性心脏病心力衰竭安全有效。

Objective To observe the effect of Trimetazidine in treatment of ischemic heart failure. Methods 90 cases of ischemic heart failure were randomly divided into observation group and control group （45 cases in each）. Both groups received conventional treatment, and observation group received trimetazidine based on the control group, before and af- ter treatment,left ventricular ejection fraction （LVEF） and left ventricular end-diastolic diameter （LVEDD） changes were ob- served,and the clinical efficacy was compared. Results After treatment, LVEDD decreased and LVEF increased in both groups and the differences were significant （ P 〈 0.05）, but the improvement in the observation group was better than that in the control group, and the differences were statistically significant （ P 〈 0.05 ）. The total effective rate in the observation group was 91.1% ,which was higher than 71.1% in the control group, and the difference was statistically significant （P 〈 0.05 ）. Conclusion Trimetazidine in treatment of ischemic heart failure is safe and effective.